RT Journal Article
SR Electronic
T1 Risk of Cardiovascular Events after Covid-19: a double-cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268448
DO 10.1101/2021.12.27.21268448
A1 Tereshchenko, Larisa G.
A1 Bishop, Adam
A1 Fisher-Campbell, Nora
A1 Levene, Jacqueline
A1 Morris, Craig C.
A1 Patel, Hetal
A1 Beeson, Erynn
A1 Blank, Jessica A.
A1 Bradner, JG N.
A1 Coblens, Michelle
A1 Corpron, Jacob W.
A1 Davison, Jenna M.
A1 Denny, Kathleen
A1 Earp, Mary S.
A1 Florea, Simeon
A1 Freeman, Howard
A1 Fuson, Olivia
A1 Guillot, Florian
A1 Haq, Kazi
A1 Hyde, Jessica
A1 Khader, Ayesha
A1 Kolseth, Clinton
A1 Kim, Morris
A1 Krol, Olivia
A1 Lin, Lisa
A1 Litwin, Liat
A1 Malik, Aneeq
A1 Mitchell, Evan
A1 Mohapatra, Aman
A1 Mullen, Cassandra
A1 Nix, Chad D
A1 Oyeyemi, Ayodele
A1 Rutlen, Christine
A1 Corley-Stampke, Lisa
A1 Tam, Ashley
A1 Van Buren, Inga
A1 Wallace, Jessica
A1 Khan, Akram
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.27.21268448.abstract
AB Objective To determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular events and all-cause mortality.Methods We conducted a retrospective double-cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection [COVID-19(+) cohort] and its documented absence [COVID-19(-) cohort]. The study investigators drew a simple random sample of records from all Oregon Health & Science University (OHSU) Healthcare patients (N=65,585) with available COVID-19 test results, performed 03.01.2020 - 09.13.2020. Exclusion criteria were age < 18y and no established OHSU care. The primary outcome was a composite of cardiovascular morbidity and mortality. All-cause mortality was the secondary outcome.Results The study population included 1355 patients (mean age 48.7±20.5 y; 770(57%) female, 977(72%) white non-Hispanic; 1072(79%) insured; 563(42%) with cardiovascular disease (CVD) history). During a median 6 months at risk, the primary composite outcome was observed in 38/319 (12%) COVID-19(+) and 65/1036 (6%) COVID-19(-) patients (p=0.001). In Cox regression adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk of the primary composite outcome (HR 1.71; 95%CI 1.06-2.78; p=0.029). Inverse-probability-weighted estimation, conditioned for 31 covariates, showed that for every COVID-19(+) patient, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19(-): average treatment effect on the treated -65.5 (95%CI -125.4 to -5.61) days; p=0.032.Conclusions Either symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes and has causal effect on all-cause mortality in a late post-COVID-19 period.ClinicalTrials.gov Identifier: NCT04555187What is already known about this subjectAcute, symptomatic COVID-19 can cause acute cardiovascular manifestations.Post-acute or “long” COVID-19 can be a debilitating disease following acute infection with a heterogenous presentation.What might this study add?Either symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes.Either symptomatic or asymptomatic SARS-CoV-2 infection has causal effect on all-cause mortality in a late post-COVID-19 period.How might this impact on clinical practice?As we begin to care for more survivors of COVID-19, we will need to better understand not only how to care for their acute symptoms and complications following infection, but also recognize future cardiovascular risk and mitigate such risk with appropriate screening and preventative measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by the National Heart Lung and Blood Institutes (NHLBI, grant number HL118277 to LGT), Medical Research Foundation of Oregon, and OHSU President Bridge funding (LGT). Oregon Clinical and Translational Research Institute grant (UL1TR002369) supported the use of REDCap.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the Oregon Health & Science University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors